ATE368466T1 - Androgensyntheseinhibitoren - Google Patents

Androgensyntheseinhibitoren

Info

Publication number
ATE368466T1
ATE368466T1 AT98903769T AT98903769T ATE368466T1 AT E368466 T1 ATE368466 T1 AT E368466T1 AT 98903769 T AT98903769 T AT 98903769T AT 98903769 T AT98903769 T AT 98903769T AT E368466 T1 ATE368466 T1 AT E368466T1
Authority
AT
Austria
Prior art keywords
androgen synthesis
synthesis inhibitors
inhibitors
prostate cancer
present
Prior art date
Application number
AT98903769T
Other languages
English (en)
Inventor
Angela Brodie
Yangzhi Ling
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE368466T1 publication Critical patent/ATE368466T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98903769T 1997-02-05 1998-02-05 Androgensyntheseinhibitoren ATE368466T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/795,932 US5994334A (en) 1997-02-05 1997-02-05 Androgen synthesis inhibitors

Publications (1)

Publication Number Publication Date
ATE368466T1 true ATE368466T1 (de) 2007-08-15

Family

ID=25166812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903769T ATE368466T1 (de) 1997-02-05 1998-02-05 Androgensyntheseinhibitoren

Country Status (11)

Country Link
US (2) US5994334A (de)
EP (1) EP1019060B1 (de)
JP (2) JP5043250B2 (de)
AT (1) ATE368466T1 (de)
AU (1) AU6045398A (de)
CA (2) CA2628607C (de)
DE (1) DE69838177T2 (de)
DK (1) DK1019060T3 (de)
ES (1) ES2290984T3 (de)
PT (1) PT1019060E (de)
WO (1) WO1998033506A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2001005364A1 (en) * 1999-07-15 2001-01-25 The Procter & Gamble Company Nitrogen-containing steroid compounds and their use to regulate hair growth
US6093421A (en) * 1999-08-31 2000-07-25 Biotics Research Corporation Maca and antler for augmenting testosterone levels
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
US6413951B2 (en) 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
WO2002000681A1 (en) * 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
AU2002361861A1 (en) * 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
EP2428519B1 (de) 2004-08-24 2015-01-21 BTG International Limited Zusammenstellung zur Herstellung von 17-Vinyl-Triflate als Zwischenprodukte
AU2006204334B2 (en) * 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
CA2637000A1 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
AU2007303219A1 (en) * 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
ES2430379T3 (es) * 2007-08-24 2013-11-20 Council Of Scientific & Industrial Research Nuevos ésteres esteroideos de 17-oximino-5-androsten-3-beta-ol
WO2009039103A2 (en) * 2007-09-17 2009-03-26 Human Pheromone Sciences, Inc. Fragrance compositions and other compositions which contain naturally occurring substances found in corals
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
EP2135933B1 (de) 2008-06-20 2013-04-03 The Procter and Gamble Company Waschzusammensetzung
BR122021011394B1 (pt) 2008-12-04 2021-09-28 Chongxi Yu Composição de alta penetração de um fármaco principal, e uso de uma hpc
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
CN102711769A (zh) 2009-09-11 2012-10-03 生态自然E·A有限公司 甾体化合物在炎性和自身免疫疾病中的应用
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
PL2709631T3 (pl) 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1
EP3572417B1 (de) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3-disubstituierte 19-nor-pregnan verbindungen, zusammensetzungen damit und verwendungen davon
KR101352635B1 (ko) * 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
ES2621528T3 (es) 2012-11-28 2017-07-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de 3-(4’-sustituido)-bencil éter de pregnenolona
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CA2902335C (en) * 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
EP2986624B1 (de) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. Neuroaktive 19-nor-steroide zur verwendung zur behandlung von krankheiten
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ME03809B (de) 2014-10-16 2021-04-20 Sage Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (de) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN107722101A (zh) * 2017-11-03 2018-02-23 郑州大学 甾体吡啶类衍生物及其制备方法和应用
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN111333696B (zh) * 2020-04-07 2021-09-24 华中药业股份有限公司 一种治疗痛风的化合物及其制备方法和用途
CN114344310B (zh) * 2021-12-02 2023-10-10 华中药业股份有限公司 一种治疗痛风的药物组合物及其制备方法与用途
US20250312409A1 (en) * 2022-05-10 2025-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2335616A (en) * 1941-11-06 1943-11-30 Parke Davis & Co Steroidal hormone intermediates and their preparation
US2664423A (en) * 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
US2707189A (en) * 1952-09-11 1955-04-26 Upjohn Co 3-keto-17beta-acetamido-4-androstene and process
NL125073C (de) * 1961-07-24
FR1381407A (fr) * 1963-10-17 1964-12-14 Roussel Uclaf Procédé de préparation de composés tétracycliques et produits obtenus par ce procédé
US3317520A (en) * 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
ATE195129T1 (de) * 1992-05-20 2000-08-15 Merck & Co Inc 4-azasteroide als 5-alpha-reduktase
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
EP0862436A1 (de) * 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituierte-6-aza-steroid 5-alpha reduktaseinhibitoren
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
CA2628607A1 (en) 1998-08-06
EP1019060B1 (de) 2007-08-01
JP2010024238A (ja) 2010-02-04
US6133280A (en) 2000-10-17
DE69838177T2 (de) 2008-04-10
EP1019060A4 (de) 2005-04-13
US5994334A (en) 1999-11-30
JP2001510471A (ja) 2001-07-31
DK1019060T3 (da) 2007-11-12
JP5043250B2 (ja) 2012-10-10
CA2279971A1 (en) 1998-08-06
WO1998033506A1 (en) 1998-08-06
AU6045398A (en) 1998-08-25
ES2290984T3 (es) 2008-02-16
CA2279971C (en) 2011-07-12
PT1019060E (pt) 2007-10-03
EP1019060A1 (de) 2000-07-19
DE69838177D1 (de) 2007-09-13
CA2628607C (en) 2011-06-07

Similar Documents

Publication Publication Date Title
DE69838177D1 (de) Androgensyntheseinhibitoren
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1107721T1 (el) Παραγωγα τυροζινης
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
DE69834024D1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
BR9714394A (pt) Inibidores da atividade enzimática de psa
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
WO2000004954A3 (de) Neue urokinase-inhibitoren
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
PT880540E (pt) 17-beta-ciclopropil-(amino/oxi)-4-azaesteroides como inibidores activos de 5-alfa-redutase e c17-c20-liase de testosterona
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2001028593A3 (en) Conjugates useful in the treatment of prostate cancer
DE3574563D1 (de) Zusammensetzungen und verbindungen zur behandlung von prostata-adenom.
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1019060

Country of ref document: EP

REN Ceased due to non-payment of the annual fee